Clinical Trial Services

CTS is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and IITs.

$1.5-2.5

billion market size

MARKET DRIVERS

  • Trend is to outsource management of clinical trials
  • Comparator drugs increasingly used over placebos
  • Increase in more expensive biologic/biosimilar drugs
  • Growth in IITs
  • Clients increasingly requiring a global solution

DIFFERENTIATORS

  • Deep well-established relationships with pharmaceutical companies
  • Global supply chain and distribution network
  • Certify product for authenticity
  • Superior pharmacovigilance and quality management knowledge
  • Deep understanding of complexity of regulatory environment
  • Expanded service sand IIT offering

Unlicensed Medicines

Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes (MAPs) for innovative new medicines and provides ‘on-demand’ access globally to medicines which remain unlicensed at the point of care.

$5-10

billion market size

MARKET DRIVERS

  • Structural growth in emerging pharmaceutical markets
  • Increased role of patient advocacy groups demanding best treatments
  • Demand for RWD
  • Geography-specific drug shortages
  • Increase in counterfeit products
  • Clients increasingly requiring a global solution

DIFFERENTIATORS

  • Broad and embedded relationships with pharmaceutical companies and pharmacists
  • Focus on mature, hospital-only products
  • Certify product for authenticity
  • Deep understanding of complexity of regulatory environment
  • Online proprietary medicines access platform

Commercial Medicines

The Group acquires global rights to niche hospital-only and critical care products, revitalising these assets around the world and returning them back to sustained growth. The Group also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

5

global products

175

local marketed licences

MARKET DRIVERS

  • Mature product divestment by large pharmaceutical companies
  • Clients increasingly requiring a global solution
  • Clients increasingly looking to partner with a regional specialist to manage the lifecycle of products/therapy area franchises, essentially outsourcing the commercial management

DIFFERENTIATORS

  • Broad and embedded relationships with pharmaceutical companies
  • Local market knowledge
  • Global supply chain and distribution network
  • Not reliant on sales force
  • Capability to convert unlicensed medicines to licensed medicines
  • Revitalisation capability